A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis - Wikidata - wikimedia - TriplyDB

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

http://www.wikidata.org/entity/Q37012710

about

Etrolizumab for induction of remission in ulcerative colitis Etrolizumab for induction of remission in ulcerative colitis The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes Advances in the development of new biologics in inflammatory bowel disease Integrin-based therapeutics: biological basis, clinical use and new drugs Hepatic manifestations of non-steroidal inflammatory bowel disease therapy Promising biological therapies for ulcerative colitis: A review of the literature Medical Therapy of Active Ulcerative Colitis Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments Review article: anti-adhesion therapies for inflammatory bowel disease Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.Etrolizumab for ulcerative colitis: the new kid on the block?New strategies for treatment of inflammatory bowel disease Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.Animal models of ulcerative colitis and their application in drug research.Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI3185, a fully human antibody to CXCR4 The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.Integrin modulators: a patent review.T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.Novel concepts in inflammatory bowel disease.Vedolizumab for the treatment of ulcerative colitis.Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target.Targeting integrins and adhesion molecules to combat inflammatory bowel disease.New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD.Emerging therapeutic targets and strategies in Crohn's disease.Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.Update on the Use of Biologic Therapy in Ulcerative Colitis.Emerging treatments for ulcerative colitis: a systematic review.Frontiers in Drug Research and Development for Inflammatory Bowel Disease.Infection risk with biologic therapy in patients with inflammatory bowel disease.

P2860

Q24186788-F73BAD7C-5B3B-464F-8CA4-EB54FB7F705E Q24187269-65D115B1-616B-4D9E-A324-46702BADD10A Q26745725-69EC0297-1D56-4855-8ACE-38AB705356DE Q26745782-15FE8086-3576-4FCF-83FD-4B99C1E4214A Q26773026-18BAB201-E40D-4D26-9061-F6B2E906BC1C Q26773684-78C7130F-18B0-4F84-A7AC-B0E9AF4AE4E7 Q26776139-B5F42DC5-CEDC-40DA-A1A9-4D8C04872052 Q26777729-468EA83A-7A39-40D7-874A-BCEDCD217F02 Q26785537-60C15D32-3BC3-4060-8676-2828252B994A Q26999705-F4557E40-9AEC-42A2-8A14-459848FE08A8 Q28084236-70A82A5E-A102-4ACB-BABB-F16090ACF82D Q28084276-F2636FB4-2FE6-47A6-9F2A-C8C9EFE7541C Q28597396-33EFB884-FE19-44EA-9D63-EC89904D7516 Q30815146-E48C2E79-7732-49D9-B7E1-AD9FFDF19438 Q34515659-D434D321-1B50-438A-B467-24F44DC0AB94 Q35069777-9A69F6C8-1CC1-4ACC-AB0E-4EFF103DB47C Q35889006-FCA0D752-081C-4A6C-8583-1AB6CA8AEE45 Q36783977-57148E28-095B-4EF8-B814-1934E00A299B Q37188711-29160F4B-FB1F-42D9-A976-5B5DDF9AC039 Q37312835-2F792787-7A5E-4118-A6DD-68999F26EB8E Q37340477-93302E11-A0A3-49B7-8B72-42965B530056 Q38132555-1EA884CB-AD4A-490B-A16D-A8CADDA8E90D Q38139612-04A146B5-7AA9-4C14-AC44-98EBB33AD7B3 Q38181018-22710AE5-FDE8-404D-AE75-B251BC16FBAA Q38186010-E94D5922-007A-45D2-B60E-934E933526E2 Q38209809-51DA3E57-E5BD-405A-B459-C9CA30B12132 Q38210630-8158CAB9-6534-4B8A-81B0-C491B215B2FF Q38248635-901F2E47-AE8B-4DD1-8656-CE2489F36B07 Q38293802-2664D8C4-6246-4F9A-8A20-D9FD7745623D Q38412914-599302A8-05EA-4F5B-B1E0-47DAC10013EF Q38436580-36756787-D400-47D1-BB0D-0C37B25AFF83 Q38478216-5473FDCC-6912-421E-824E-F527A86CD295 Q38696392-D7A9491F-1B94-4E34-BB8B-CF80DB7F9FDE Q38715286-BC4DC3F3-1E91-4841-AD27-9B86E6A55E59 Q38744708-72E6E065-35F6-4961-9286-3378DDED9ED0 Q38814438-1C96D00E-AE8F-4BB3-9044-BD1C6DD6CB70 Q39102244-46942923-976B-4D12-845D-867120D7AAEA Q39306383-83863D34-F843-4136-8860-4911EA2583E2 Q39424463-19438D6C-B034-4177-8D26-335EF2AF5B14 Q39429997-EB3A81AD-E203-4435-B581-D319FA61D42E

P2860

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

http://www.wikidata.org/entity/Q37012710

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 June 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A randomised phase I study of ...... e to severe ulcerative colitis

@en

A randomised phase I study of etrolizumab

@nl

type

label

A randomised phase I study of ...... e to severe ulcerative colitis

@en

A randomised phase I study of etrolizumab

@nl

prefLabel

A randomised phase I study of ...... e to severe ulcerative colitis

@en

A randomised phase I study of etrolizumab

@nl

P1433

Q37012710-F01328DF-C450-452C-A225-FFB390DFDDF5

P1476

Q37012710-D6B6CA05-6C01-411A-9018-7CBB8E8716B8

P2093

Q37012710-087E3F70-5B05-44BE-A3B0-E4FEC9A9312A

Q37012710-0993A41B-B5D0-498F-B7CB-BD2D8AF1F4A4

Q37012710-3583734B-503F-4F11-9EDA-F4AD61322B34

Q37012710-3B5DEFC2-D3EC-44BD-ACF7-1A6F49F8F63D

Q37012710-43111CF5-56A0-449D-8ED9-5E7E616AC8A4

Q37012710-435E93F3-7D82-4720-8EA3-98CE11DF7B01

Q37012710-4CF8DF06-9370-4FB4-87F2-F7F4C548C270

Q37012710-5AA853BE-AA14-4476-89C9-3C62EC9269EC

Q37012710-8B401BA6-5982-48ED-B3C5-BF8270015FE6

Q37012710-9BD4D122-A461-4DE1-8119-2CFD23795568

P2860

Q37012710-052460C8-A08A-4355-9B22-AB97846D2D36

Q37012710-0596212F-C6DA-4CAF-A95B-EC79694881E3

Q37012710-0E0131BE-1663-4645-ACD3-4BF6487CFA36

Q37012710-11711F5C-E60E-4CA9-8C39-6ABA0AD1E084

Q37012710-1177B1E4-3ED5-41F9-A7C0-9C98E4E1186E

Q37012710-21A816DA-70DD-44D8-AB37-DA08C731E206

Q37012710-34DCA4F5-A446-4F47-B586-4F32ECC04D1E

Q37012710-39DD3517-B6AA-4000-B16E-D983B6B7B229

Q37012710-45DF994A-CC94-445F-A337-4685462C1A3E

Q37012710-46E70C04-D6E5-422A-8B3D-CEB8AF4F8755

P304

Q37012710-8362DDEB-870B-4E15-BEC1-18E3CCC6F8E3

P31

Q37012710-4E74FEB1-77A1-4097-A9C1-9B1AA9118139

P356

Q37012710-9F1E58BA-BABF-449D-8DEA-E7A8CDE45CB5

P407

Q37012710-B89DBBBE-3545-424D-BE60-C23CA657CC37

P433

Q37012710-4EBF1904-A7D4-49E9-80CF-F3F920152EE4

P478

Q37012710-D3D42236-8061-4145-B38D-8CE42F8D3D3D

P577

Q37012710-24B4BCD3-19D3-4B68-9EA4-B118EE483991

P5875

Q37012710-3A5C8772-BB1D-448E-A1F3-69E82DB9071F

P698

Q37012710-F6A1DBF5-33EA-44A8-999C-72E880FB2B23

P932

Q37012710-0F6FB2D0-8369-40DF-875F-5B9A3CD3CFB0

P356

GUTJNL-2011-301769

P1433

P1476

A randomised phase I study of ...... e to severe ulcerative colitis

@en

P2093

Andreas Sturm

http://www.w3.org/2001/XMLSchema#string

Brian Bressler

http://www.w3.org/2001/XMLSchema#string

Daan W Hommes

http://www.w3.org/2001/XMLSchema#string

Daniel C Baumgart

http://www.w3.org/2001/XMLSchema#string

Diana Luca

http://www.w3.org/2001/XMLSchema#string

Dimitri Danilenko

http://www.w3.org/2001/XMLSchema#string

Jackson Egen

http://www.w3.org/2001/XMLSchema#string

Jennifer Visich

http://www.w3.org/2001/XMLSchema#string

John C Mansfield

http://www.w3.org/2001/XMLSchema#string

Marna Williams

http://www.w3.org/2001/XMLSchema#string

P2860

A key role for E-cadherin in intestinal homeostasis and Paneth cell maturation

Inflammatory bowel disease: clinical aspects and established and evolving therapies

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Role of integrin alpha 4 beta 7/alpha 4 beta P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering

Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing

Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region

A family of beta 7 integrins on human mucosal lymphocytes

Adhesion to vascular cell adhesion molecule 1 and fibronectin. Comparison of alpha 4 beta 1 (VLA-4) and alpha 4 beta 7 on the human B cell line JY

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

T-Cell Function and Migration — Two Sides of the Same Coin

P304

1122-1130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2011-301769

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227708767

http://www.w3.org/2001/XMLSchema#string

P698

22717454

http://www.w3.org/2001/XMLSchema#string

P932

3711369

http://www.w3.org/2001/XMLSchema#string